CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 03, 2021	Jun. 27, 2020
Cash Flows from Operating Activities:
Net (loss) income	$ (4,454)	$ 10,527
Non-cash items:
Depreciation and amortization	25,033	20,724
Amortization of fair value inventory step-up	5,295	0
Impairment of assets	5,144	1,028
Share-based compensation expense	6,828	6,167
Amortization of deferred finance costs	1,019	147
(Benefit) provision for losses on inventory	(544)	1,452
Gains on divestitures and sale of assets	(9,603)	0
Contingent consideration expense	9,774	0
Other non-cash operating activities	(355)	(841)
Change in operating assets and liabilities:
Change in accounts receivable	(5,342)	25,067
Change in inventories	(8,553)	(24,557)
Change in prepaid income taxes	2,121	(3,544)
Change in other assets and other liabilities	1,256	865
Change in accounts payable and accrued expenses	(29,299)	(25,223)
Net cash (used in) provided by operating activities	(1,680)	11,812
Cash Flows from Investing Activities:
Capital expenditures	(13,919)	(7,696)
Acquisition	(2,500)	(16,606)
Proceeds from divestitures	0	0
Proceeds from sale of property, plant and equipment	568	406
Net cash used in investing activities	(15,851)	(23,896)
Cash Flows from Financing Activities:
Net increase in short-term loans	0	150,000
Repayment of term loan borrowings	(4,375)	(4,375)
Proceeds from employee stock purchase plan	2,210	2,144
Proceeds from exercise of stock options	500	1,193
Other	31	(11)
Net cash (used in) provided by financing activities	(1,634)	148,951
Effect of exchange rates on cash and cash equivalents	322	1,547
Net Change in Cash and Cash Equivalents	(18,843)	138,414
Cash and Cash Equivalents at Beginning of Period	192,305	137,311
Cash and Cash Equivalents at End of Period	173,462	275,725
Supplemental Disclosures of Cash Flow Information:
Interest paid	1,482	2,780
Income taxes paid	14,494	2,063
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 3,203	$ 2,364